15 million doses of Johnson & Johnson single-dose vaccine thrown away. It happened in Baltimona, in the manufacturing plant run by Emergent BioSolutions, partner of Johnson & Johnson itself and of AstraZeneca. As reported in the past few hours by the New York Times, at the base of the accident, which occurred a few weeks ago, there would be a human error in the preparation of the doses, carried out by confusing the ingredients of the J&J vaccine with those of AstraZeneca, recently authorized for administration also in the United States.
The two vaccines use the same technology that employs the harmless version of a virus – known as a vector – that is passed into cells to release a protein that stimulates the immune system to make antibodies. But the carriers of Johnson and Johnson and AstraZeneca are biologically different and not interchangeable.
The incident is investigating Food And Drug Administration, the US government agency that deals with the regulation of food and pharmaceutical products. Meantime, the authorities have blocked the authorization for vaccine production at the plant, which also leads to a halt to the planning of future deliveries of Johnson & Johnson vaccine doses to the US.
For its part, Johnson & Johnson stated in a press release that “the company quality control system identified a batch of pharmaceutical substance that did not meet the quality standards, at Emergent BioSolutions, site currently not authorized to produce doses for our Covid-19 vaccine“.
The error, it is also specified, would have no bearing on the Johnson & Johnson doses currently supplied and administered in the United States, as they are produced in the plant located in the Netherlands., in the manner prescribed by the US federal authorities. Johnson & Johnson has meanwhile taken steps to strengthen its control over the work of the Emergent BioSolutions and avoid further drops in quality.
In Italy, according to the plan of the Ministry of Health, the single-dose Covid-19 vaccine produced by Johnson & Johnson should make its arrival from next April 16, date from which they are expected approximately 7.3 million doses by June and approximately 15.9 million in the third quarter. Confirmation is now awaited that everything will proceed, in this sense, according to the planned plans.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
